MedTrace Logo

Modification of the Human Colon and Oral Microbiome by Allogenic HSCT

NCT03942159 · Status: UNKNOWN · Type: OBSERVATIONAL · Enrollment: 15

Last updated 2020-04-07

No results posted yet for this study

Summary

Allogenic HSCT brings significant changes in biodiversity and composition of the gut microbiome through antibiotic usage, the mucosal damage due to the chemo- and radiotherapy toxicity; compromised oral nutritional intake and graft-versus-host disease with gut damage as the complication. Aim of the study is to investigate the composition of the microbiota in both recipient and nursing relative donor, reveal changes in biodiversity after HSCT via 3-time points V3V4 16S rRNA and NGS sequencing of the colon and oral swabs, 3-indoxyl-sulfate measurement in the urine.

Conditions

  • Human Microbiome
  • HSCT

Sponsors & Collaborators

  • Federal Research Institute of Pediatric Hematology, Oncology and Immunology

    lead OTHER

Principal Investigators

  • Michael Maschan, PhD · National Research Center for Pediatric Hematology , Moscow, Russian Federation

Eligibility

Max Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2019-05-14
Primary Completion
2021-03-31
Completion
2023-03-31

Countries

  • Russia

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03942159 on ClinicalTrials.gov